Industry News
Pharmaceutical Industry News
Trump Plans to Fire F.D.A. Commissioner Marty Makary
Dr. Makary has been a supporter of the Make American Healthy Again Movement but made some enemies in the administration over vaping, the abortion pill and rejections of new drugs.
Eversana Intouch, the AI-powered…
Eversana Intouch, the AI-powered marketing agency arm of Eversana, pulled seasoned advertising exec Mike Guarino to serve as its new CEO.
During the weeklong stay by the…
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepristone after a shock appeals court decision last Friday, scores of experts, industry heavyweights and former regulators have
About Half of Patients with Metastatic Lung Cancer Don’t Get Treatment, Study Finds
New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?
Strengthening core CDO values for…
Strengthening core CDO values for cell line development
Explore how targeted protein…
Explore how targeted protein degradation is reshaping drug discovery, enabling new approaches for difficult targets and advancing novel therapeutic modalities.
Gilead raised its previous…
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a high-flying launch thus far.
With an FDA decision date looming…
With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a lawsuit against its U.S. commercial partner, NS Pharma, and its parent company, Nippon Shinyaku.
Daiichi Sankyo is poised to report…
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a $610 million hit linked to its precautionary antibody-drug conjugate manufacturing strategy.
Fierce Pharma’s Fraiser…
Fierce Pharma’s Fraiser Kansteiner catches up with KPMG’s Chris Young to discuss the latest pharma tariff developments and how Big Pharma and small- to mid-sized drugmakers are responding.
After losing the top spot in March…
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the drug with the highest level of ad spending.
You’ve heard of Gen Z, but now…
You’ve heard of Gen Z, but now Johnson & Johnson wants you to be aware of “Generation Fine” as it looks to boost understanding around depression treatment.
Cancer treatments with high levels…
Cancer treatments with high levels of physician awareness at launch maintain their advantage over drugs that are yet to gain widespread recognition when they come to market, a ZoomRx analysis found.
GSK is teaming up with “Modern…
GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about the risks of meningococcal disease.
Louisiana Asks Supreme Court to Halt Abortion Pill Access by Mail
The request comes after a federal appeals court temporarily blocked a Food and Drug Administration regulation that has greatly expanded access to the abortion pill mifepristone.
Summit’s PD-1xVEGF study…
Summit's PD-1xVEGF study surprisingly missed its mark at an interim analysis. UCB will pay $2 billion upfront to buy Candid Therapeutics, which has aggregated a group of Chinese assets. J&J eliminated two CD20 CAR-T programs
With an eye on the lucrative U.S….
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
After a surprise rejection in…
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of
The FDA has hit Alnylam with an…
The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
Insulet has always been a strong…
Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.